Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Regenerative Medicine Clinical Candidate CTR-107 (Noregen™) for Retinal Diseases

Caeregen Therapeutics has recently received a significant boost in funding for their regenerative medicine clinical candidate, CTR-107 (Noregen™). The company was awarded a $1.4 million Phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute. &nbsp This grant will play a crucial role in advancing the development of CTR-107, ..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 18.
  • textsms

Current Surgical Receives $400k Grant from NIH's National Cancer Institute to Develop Surgery Platform for Early-Stage Cancer

Current Surgical Inc., a medical technology company, has been awarded a $400,000 grant by the National Institutes of Health's National Cancer Institute (NCI) to support the advancement of their surgical platform for early-stage cancer. The grant will be utilized to further develop and validate the company's innovative technology in a preclinical setting. With over 18 million new cases detected a..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 13.
  • textsms
Anixa Biosciences, 차세대 치료법으로 난소암 치료의 새로운 방향

Anixa Biosciences, 차세대 치료법으로 난소암 치료의 새로운 방향

Anixa Biosciences는 암의 치료와 예방에 집중하는 임상 단계의 바이오기술 회사로, 지난 5월 22일 H. Lee Moffitt Cancer Center & Research Institute와 함께 진행 중인 난소암 치료를 위한 새로운 CAR-T(Cimeric Antigen Receptor T-cell) 치료법 임상 시험에서 두 번째 환자의 치료를 시작했다고 발표했습니다. 이 연구(NCT05316129)는 Follicle Stimulating Hormone receptor T-cells의 최대 허용량을 평가하고 임상 활동을 예비적으로 평가하기 위한 1상 복용 상승 시험입니다. 모든 환자들은 치료가 진행되고 있는 상태로, 적어도 두 가지, 종종 더 많은 치료를 실패한 상태입니다. 현재 시험에서 ..

  • format_list_bulleted Pharmacology/News
  • · 2023. 5. 23.
  • textsms